News IPO plan evaporates as private equity firm buys Stada Stada has confirmed it isn't going ahead with an IPO, as its two private equity owners have just agreed to sell a majority stake to a third.
News ESC: Real-world study gives Wegovy edge over Lilly rival Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy works better than Eli Lilly's fast-growing rival Zepbound.
News Sanofi breaks new ground for BTK drugs with ITP approval Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved for rare platelet-busting disease immune thrombocytopenia.
News Dose-at-home Leqembi for Alzheimer's cleared in US Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?
News Outlook blindsided as FDA blocks wet AMD drug once again Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.
News Lilly pauses Mounjaro orders in UK ahead of price hike Lilly has paused shipments of weight loss therapy Mounjaro to the UK to prevent stockpiling ahead of a price rise, but patients report shortages.
News Jemperli label extended to include rectal cancer GSK's PD-1 inhibitor Jemperli has been cleared by the FDA as the first pre-operative cancer immunotherapy for rectal cancer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.